Creative Planning Has $1.25 Million Holdings in DaVita Inc. (NYSE:DVA)

Creative Planning trimmed its position in DaVita Inc. (NYSE:DVA) by 8.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,600 shares of the company’s stock after selling 697 shares during the quarter. Creative Planning’s holdings in DaVita were worth $1,246,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Harvard Management Co. Inc. purchased a new position in DaVita during the 2nd quarter worth approximately $55,115,000. Lazard Asset Management LLC raised its position in DaVita by 147.3% during the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after buying an additional 153,008 shares during the period. Jupiter Asset Management Ltd. lifted its stake in DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after acquiring an additional 111,311 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in DaVita during the 2nd quarter worth about $9,615,000. Finally, Hennessy Advisors Inc. purchased a new position in DaVita during the 2nd quarter valued at about $8,439,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

NYSE DVA opened at $141.16 on Thursday. DaVita Inc. has a fifty-two week low of $76.17 and a fifty-two week high of $168.50. The stock’s 50-day moving average is $158.21 and its two-hundred day moving average is $146.02. The firm has a market cap of $11.84 billion, a P/E ratio of 15.03, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 77.00% and a net margin of 6.86%. The company had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter last year, the firm posted $2.85 earnings per share. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Bank of America raised their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, UBS Group upped their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus price target of $159.00.

Insider Buying and Selling

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 in the last quarter. 2.00% of the stock is currently owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.